GSK Q4 earnings beat expectations, driven by strong performance of HIV and asthma drugs
Show original
Glonghui, February 4th|British pharmaceutical giant GlaxoSmithKline released its financial report on Wednesday, showing that thanks to the strong performance of its HIV and asthma drugs, the company's fourth-quarter profits exceeded expectations. The UK-based pharmaceutical company stated that adjusted earnings per share, excluding certain items, were 25.5 pence, higher than analysts' expectations. The company expects profit growth this year to be between 7% and 9%. Previously, some analysts had forecast earnings per share growth guidance of around 6% to 8%. Newly appointed CEO Luke Miels has set a highly ambitious target that is likely to be surpassed, and sales of the cancer drug Blenrep are also expected to boost revenue this year.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
PoolX: Earn new token airdrops
Lock your assets and earn 10%+ APR
Lock now!
You may also like
Vitalik: No need for more copy-paste EVM chains; focus should be on application chains and institutional-grade L2s
ForesightNews•2026/02/05 09:38
U.S. semiconductor and chip equipment stocks rise in pre-market trading
格隆汇•2026/02/05 09:38
Trending news
MoreCrypto prices
MoreBitcoin
BTC
$71,389.32
-5.93%
Ethereum
ETH
$2,130.56
-5.36%
Tether USDt
USDT
$0.9983
-0.02%
BNB
BNB
$696.32
-7.84%
XRP
XRP
$1.42
-11.06%
USDC
USDC
$0.9996
+0.00%
Solana
SOL
$92.33
-4.67%
TRON
TRX
$0.2809
-2.02%
Dogecoin
DOGE
$0.1019
-5.33%
Bitcoin Cash
BCH
$524.58
-0.52%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now